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Differences in age and sex distribution as well as FAB (French-
American-British classification) types have been reported for acute
leukemias in several countries. We studied the demographics and
response to treatment of patients with acute myeloid leukemia (AML)
and acute lymphoblastic leukemia (ALL) between 1989 and 2000 in
Teresina, Piauí, and compared these results with reports from Brazil
and other countries. Complete data concerning 345 patients (230
ALL, 115 AML) were reviewed. AML occurred predominantly in
adults (77%), with a median age of 34 years, similar to that found in the
southeast of Brazil but lower than the median age in the United States
and Europe (52 years). FAB distribution was similar in children and
adults and FAB-M2 was the most common type, as also found in
Japan. The high frequency of FAB-M3 described in most Brazilian
studies and for Hispanics in the United States was not observed.
Overall survival for adults was 40%, similar to other studies in Brazil.
A high mortality rate was observed during induction. No clinical or
hematological parameter influenced survival in the Cox model. ALL
presented the characteristic peak of incidence between 2-8 years. Most
of the cases were CD10+ pre-B ALL. In 25%, abnormal expression of
myeloid antigens was observed. Only 10% of the patients were older
than 30 years. Overall survival was better for children. Age and
leukocyte count were independent prognostic factors. These data
demonstrate that, although there are regional peculiarities, the applica-
tion of standardized treatments and good supportive care make it










Publication supported by FAPESP.
Received May 24, 2002




 Acute myeloid leukemia
 Epidemiology
Introduction
Geographical variations have been de-
scribed for age and sex distribution as well as
FAB (French-American-British classifica-
tion) subtypes of acute leukemias, possibly
due to ethnic and environmental factors.
Acute lymphoblastic leukemia (ALL), the
most common type of acute leukemia in
childhood, has its peak of incidence between
1 and 4 years in most countries (1). The most
common phenotype is CD10+ pre-B ALL (1-
3). The frequency of T-ALL increases with
age. Children show a better response to treat-
ment than adults (1).
Regional variations have been described
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for acute myeloid leukemia (AML). FAB-
M2 is the most common type of AML in
Japan and its frequency is higher in children
than in adults (4), a fact that was not ob-
served in Australia (5). Promyelocytic leu-
kemia (FAB-M3) shows a remarkably high
frequency among Hispanics in the United
States (6) and in several countries in South
America including Brazil (7-9).
Brazil is a large country with striking
differences in climate, ethnic heterogeneity
and degree of industrialization. In the pres-
ent study we describe the demographic fea-
tures and response to treatment of acute
leukemias (children and adults, ALL and
AML) observed at a large regional hospital
in Teresina, PI, northern Brazil, which repre-
sents the only cancer center for a region of
about 3 million people. We compared sev-
eral of these features with results described
for other regions of Brazil, especially Cam-
pinas, located in the subtropical, highly in-
dustrialized southeast.
Patients and Methods
All newly diagnosed patients with ALL
and AML treated at the São Marcos Hospital
(the only hospital that treats acute leukemias
in the region), Teresina, PI, from January
1989 to December 2000 were enrolled in
this retrospective study. Teresina is the capi-
tal of a region with 3 million inhabitants
located at 5º latitude south. Exclusion crite-
ria were the absence of complete medical
records or bone marrow smears for review.
Secondary leukemias (cases with a past his-
tory of chemotherapy or radiotherapy or my-
elodysplasia) and chronic myeloid leukemia
in blast crisis were also excluded.
The following parameters were collected
for each patient: age, sex, presence of fever
and organomegalies, body mass index (weight/
height squared) and peripheral blood counts.
The diagnosis of the type of leukemia was
made according to the guidelines of the In-
ternational Council for Standardization in
Haematology (10): a diagnosis of acute leu-
kemia was made when bone marrow blasts
were above 30%. Bone marrow smears were
stained with Wright-Giemsa, periodic acid-
Schiff, Sudan black, and alpha-naphthyl-ac-
etate esterase, pH 7.4. Cases with blasts
negative for Sudan black and alpha-naph-
thyl-acetate esterase were considered to be
ALL. All smears were reviewed and classi-
fied according to FAB criteria. Since 1998,
immunophenotyping was performed in child-
hood ALL patients using monoclonal anti-
bodies to the following antigens: CD20,
CD22, CD10, cytoplasmic IgM, CD2, CD3,
CD5, CD7, CD34, HLA-DR, CD13, CD14,
CD15, CD33 and myeloperoxidase. Immu-
nophenotyping was carried out by flow cy-
tometry using a FACscan apparatus and 2-
color routine procedures.
Overall survival was calculated by the
Kaplan-Meier method for all patients ac-
cording to date of diagnosis and date of
death or last follow-up.
Patients wit ALL aged less than 18 years
were treated according to the Brazilian Pro-
tocol for ALL (11). Adults with ALL were
treated according to the German Protocol
(12). Children with AML were treated ac-
cording to the BFM-83 study (13) and adults
received 150 mg/m2 cytosine arabinoside (ara-
C) for 7 days and 50 mg/m2 daunorubicin for 3
days followed by high dose ara-C (9,14).
The data on AML were compared with a
monoinstitutional study of patients from
Campinas, SP, southeast region (15), treated
according to the TAD9 Protocol (using ara-
C, daunorubicin, 6-thioguanin) from the Ger-
man AML Study Group.
The project was approved by the Hospi-
tal Ethics Committee.
Statistical analysis
First, descriptive statistics were applied
to all the parameters analyzed. The frequen-
cies of FAB types in Teresina and Campinas
were compared by the chi-square test. Sur-
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vival was analyzed by the Kaplan-Meier
method. Univariate and multivariate analy-
sis for the features influencing survival in
ALL and AML was performed according to
the proportional hazard model of Cox (16).
Results
Acute myeloid leukemia
Complete charts and smears were re-
trieved for 115 patients. Their clinical fea-
tures are shown in Table 1. The majority of
the patients were adults (Figure 1). The male:
female ratio was similar for children and
adults. Only 9 patients (4 children and 5
adults) had a low body mass index. The FAB
subtypes of the patients are shown in Table 2
compared to those found in the study from
Campinas (15). A similar distribution of FAB
subtypes was found in children and adults in
Teresina (P = 0.20). The most common type
was FAB-M2 (32.8%), followed by FAB-
M4 and FAB-M5 (15.6% each). Among the
patients from Campinas, the most common
type was FAB-M4 (32.4%) followed by FAB-
M3 (21.1%). These differences between
Campinas and Teresina were statistically sig-
nificant (P<0.0001).
Overall survival was 40% among the pa-
tients from Teresina, including children and
adults. There was no difference in survival
according to age (Figure 2). However, 20 pa-
tients (17%) died within the first 2 months
after diagnosis. In univariate analysis, none of
the parameters analyzed showed an influence
on survival. However, when the patients were
stratified for FAB subtype there was a positive
association between subtype and age.
When the results of chemotherapy (Figure
3) were compared with those for the cases
from the Campinas study (age-matched), no
difference in outcome was observed (P = 0.22).
Acute lymphoblastic leukemia
During the study period, 230 cases were
Table 1. Clinical features of the patients with acute
myeloid leukemia from Teresina.












Enlarged lymph nodes 9
Hematocrit (%) 20 (6-43)
Leukocytes x 109/l 12.6 (0.6-76.0)
Platelets x 109/l 29 (1-295)
Data are reported as median (range) or number of
patients.
Table 2. Comparison of FAB subtypes of acute
myeloid leukemia patients from Campinas and
Teresina.









Table 3. Clinical characteristics of the patients with
acute lymphoblastic leukemia.










Enlarged lymph nodes 130
Hepatomegaly 106
Splenomegaly 122
Hematocrit (%) 22 (6-48)
Leukocytes x 109/l 18.6 (0.3-95)
Platelets x 109/l 36 (2-390)
Data are reported as median (range) or number of
patients.
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was above 50 x 109/l. A low body mass index
was observed in only 11 cases.
Immunophenotyping was performed in
31 cases. Among them, 26 were of the B-cell
lineage (24 of them CD10+) and 5 were T-
ALL. Abnormal expression of myeloid anti-
gens was observed (CD13 and/or CD33) in
one T-ALL and in 7 B-derived ALL cases.
Survival analysis demonstrated a better
survival for children than for adults (Figure
5), with a 10-year survival rate of 52% for
the former. Mortality during induction was
11%. In univariate analysis the peripheral
leukocyte count at diagnosis and patient age
showed an influence on survival (R = 0.1,
P = 0.002 and R = 0.11, P = 0.0015, respec-
tively). In multivariate analysis, both param-
eters remained significant.
Discussion
This retrospective study covered a period
of eleven years and the results are representa-
tive for the entire region of Teresina, Piauí.
This region is located in the north of Brazil, at
the Equator, in an agricultural region with a
low per capita income. However, the São
Marcos Hospital is well equipped for chemo-
therapy and supportive care. During the study
period, the patients with ALL were almost
twice the number of patients with AML.
AML was predominant in adults, with a
median age lower than that observed for the
United States (6) but similar to that observed
in other Brazilian studies (9,15,17,18). The
incidence of AML increases with age and is
more frequent above 60 years (18). This is
probably due to a higher life expectancy and
increasing environmental exposure to car-
cinogens. Life expectancy is lower in Brazil,
especially in the north and northeast regions
when compared to Europe or the United
States. Existing epidemiological data refer
to a lower incidence of AML in Brazil. This
may be more probably due to the absence of
the peak of incidence among old people
observed in developed countries than to
Figure 2. Overall survival of the patients with acute myeloid leukemia in Teresina. Children
(<15 years), adults (15-60 years), and patients >60 years are treated as separate groups.
treated in Teresina. Their clinical features
are presented in Table 3. Most patients (77%)
were less than 18 years old (Figure 4) and
were treated according to the Brazilian Pro-
tocol for Childhood ALL (10). There was a
predominance of males among both children
and adults. Organomegaly was very frequent.




















Figure 1. Age distribution of the patients with acute myeloid leukemia in Teresina com-
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Figure 4. Age distribution of the acute lymphoblastic leukemia
patients. There was a predominance of children, with a peak be-
tween 2 and 8 years. Most cases were below 30 years.
Figure 5. Survival of patients with acute lymphoblastic leukemia.
Children had a significant better survival than adults.
Figure 3. Comparison of the survival of patients from Teresina and
Campinas with acute myeloid leukemia. Although a high mortality
rate was observed during the first 2 months, those achieving com-























































Braz J Med Biol Res 36(3) 2003
M.F.N. Rego et al.
underdiagnosis, as stated by Fagundes (17).
Likewise, also myelodysplastic syndromes
in Brazil occur at a younger age than in these
countries (19).
The distribution of FAB subtypes was simi-
lar in children and adults. Since in Teresina no
immunophenotyping was performed in adult
leukemia patients, some cases of AML FAB-
M0 were probably misdiagnosed. But as the
expected frequency of this subtype is low, it
did not significantly change the relative fre-
quency of the more common FAB types. How-
ever, a low proportion of FAB-M3 was ob-
served. This is uncommon for what has been
described in other regions of Brazil (8,9,15,17,
18,20), in Latin America (7) or among Hispan-
ics in the United States (6). Although no cyto-
genetic diagnosis was performed, the morpho-
logical diagnosis of promyelocytic leukemia
has been considered highly reliable and repro-
ducible (6,21). Therefore, one may speculate
that perhaps the patients with promyelocytic
leukemia may have died from bleeding before
they reached the reference center for treat-
ment. The FAB-type distribution between Cam-
pinas (southeast) and Teresina (north) also
presented differences. In the former, FAB-M4
was more common, whereas in the latter FAB-
M2 was predominant. A similar discrepancy
was observed in the study by Nakase et al. (5)
where FAB-M2 was more frequent in Japa-
nese patients and FAB-M4 was more common
in Australia. As the concentration of Amer-
indians is higher in the north of Brazil than in
the southeast (22), one may speculate that
AML FAB-M2 is more common in Orientals
and Amerindians. One could also suppose that
in Piauí, an essentially agricultural region,
people are exposed to different carcinogens
than in the southeast, where industrial
genotoxins are present. Therefore, the ethnic
composition and environmental factors could
play a role in this distribution. Although a high
mortality was observed during induction treat-
ment, the overall survival of the patients achiev-
ing complete remission was good and similar
to that observed in other regions of Brazil
(9,15,17). A high mortality rate during induc-
tion therapy was also found in these studies,
mainly due to infection. A high frequency of
fever and infection was observed in these
patients at diagnosis, explaining the poor per-
formance obtained during induction therapy.
Most patients with ALL were children,
and even most of the cases considered as
“adults” were below 30 years old. A peak of
incidence between 2-10 years was found, as
observed in most studies around the world
but not in Africa (23). This pattern of inci-
dence has been well established but has only
recently emerged among African American
and Japanese children (1,4). Only few cases
were older than 30 years, in contrast to the
United States and Europe, where a small
peak of incidence emerges above 50 years
(1,5). Most cases where immunophenotyp-
ing was performed were common ALL
(CD19/CD10+). Also, the pattern of aber-
rant expression of myeloid antigens was simi-
lar to that observed in other studies (1-3).
Age and peripheral leukocyte counts were
the most important factors influencing out-
come in the patients.
Children were treated according to the
Brazilian Protocol for Childhood ALL, a
nationwide study for ALL treatment that has
been successful and up-to-date, permitting
the participating centers to obtain treatment
results comparable to those observed in other
countries. The survival rate, however, was
below what was expected for this protocol.
Mortality during induction was low, but sev-
eral patients died during maintenance treat-
ment or relapsed. This is in agreement with
that expected for patients with a poor socio-
economic status, among whom tolerance of
and compliance with maintenance treatment
are impaired, as stated by Viana et al. (24).
We conclude from these results that AML
shows more geographical variation than ALL.
Furthermore, the use of state-of-the art pro-
tocols and good supportive care are impor-
tant for achieving a successful treatment out-
come.
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